Nanomerics
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
30-34 New Bridge St, London, Greater Lon...Phone Number
+44 2033972183Website
www.nanomerics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Nanomerics
Nanomerics is a clinical stage pharmaceutical company specializing in the development of precision medicines using its proprietary Molecular Envelope Technology platform. The company focuses on therapeutic pipelines for ophthalmology and CNS conditions, enhancing drug efficacy and safety. Nanomerics also addresses important medical needs through its pipeline and partnered programs, including non-addictive pain therapies and treatments for degenerative eye conditions. Additionally, the company offers non-medical applications such as Molecular Masks to minimize viral infection risks.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nanomerics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Nanomerics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Nanomerics launches new products
Funding: Get notified immidiatlly once Nanomerics has new funding data
Click to see if Nanomerics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Nanomerics recently announced quarterly report
Check if Nanomerics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Nanomerics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Nanomerics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Nanomerics as Masked Content
Find more new buyers
Compare Similar Companies to Nanomerics
Compare insights from companies similar to Nanomerics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nanomerics
<$5M
11-50
Private
-
2010
N/A
Company Profile Activity
Activity Insights
Nanomerics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nanomerics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nanomerics.
Nanomerics Tech Stack
A closer look at the technologies used by Nanomerics
Nanomerics News & Media
Allergic Conjunctivitis Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Bausch & Lomb, Aldeyra, Vanda, Allakos, Regeneron, JW, Nanomerics, OKYO Pharma
The allergic conjunctivitis market is anticipated to grow in the coming years owing to the increased prevalence, better disease understanding along with the current advancements in the treatment. LAS VEGAS, Sept. 4, 2023 /PRNewswire/ -- DelveInsight's Allergic Conjunctivitis Market...Virpax Successfully Completes Initial Preclinical Studies for VRP324
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, CNS disorders and anti-viral indications, reported preclinical pharmacokinetics (PK) results for VRP324 (MET-CBD), a nose-to-brain delivery platform for CBD for the management of seizures in children and adults. In this preclinical PK study, VRP324 was able to deliver cannabidiol (CBD) to the bNanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)
LONDON, UK / ACCESSWIRE / March 22, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced the receipt of a further milestone payment on agreeing the expansion of its anti-viral spray licence (AnQlar™) to Virpax Pharmaceuticals (NASDAQ:VRPX).Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management as well as PTSD, CNS disorders and anti-viral indications, expanded its exclusive license agreement for AnQlar™ with Nanomerics Ltd., providing Virpax with the worldwide rights for development and commercialization. Virpax has completed in-vitro, ex-vivo (human mucosal cells), and in-vivo (rats)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nanomerics
Sign Up For FreeTo access detailed company insights
Nanomerics is a clinical stage pharmaceutical company specializing in the development of precision medicines using its proprietary Molecular Envelope Technology platform. The company focuses on therapeutic pipelines for ophthalmology and CNS conditions, enhancing drug efficacy and safety. Nanomerics also addresses important medical needs through it... Read More
